# Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

> **NCT07711002** · PHASE3 · NOT_YET_RECRUITING · sponsor: **AstraZeneca** · enrollment: 1330 (estimated)

## Conditions studied

- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

## Interventions

- **DRUG:** Saruparib
- **OTHER:** Placebo
- **DRUG:** Enzalutamide
- **DRUG:** Darolutamide
- **DRUG:** Abiraterone

## Key facts

- **NCT ID:** NCT07711002
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2031-06-17
- **Final completion:** 2033-06-14
- **Target enrollment:** 1330 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07711002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07711002, "Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07711002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*